Patents Represented by Attorney M. Williams
  • Patent number: 6500808
    Abstract: The invention relates to zinc-containing antiviral compositions and methods of treating viral infections. More specifically, the invention provides compositions and methods useful for ameliorating the symptoms of individuals suffering from infection with a broad range of viruses. Examples of viruses against which the compounds of the invention are active include rhinoviruses, varicella zoster, immunodeficiency viruses, including HIV.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: December 31, 2002
    Assignee: Alpha Solar Corporation
    Inventor: Harold Killam
  • Patent number: 6498020
    Abstract: The present invention relates to a fusion protein comprising a first amino acid sequence comprising the sequence of the C-terminal 40 amino acids of bovine IF1 ATPase inhibitor protein, and a second amino acid sequence not naturally associated with the first region. The invention further relates to methods for preparing an immunoglobulin comprising immunizing an animal with the fusion protein and recovering immunoglobulin specific for a region of the fusion protein.
    Type: Grant
    Filed: December 27, 1999
    Date of Patent: December 24, 2002
    Assignee: Medical Research Council
    Inventors: John Walker, Bruno Miroux
  • Patent number: 6495351
    Abstract: A loading system for providing a cell suitable for delivery of an agent to a vertebrate, the system comprise a loading module for loading a cell with an agent; and a sensitisation module in fluid communication with the loading module, the sensitisation module for sensitising a cell to an energy field, such that said cell is induced to release the agent upon exposure to said energy field. The system can be used to transform a cell, such as a red blood cell, into a delivery vehicle for delivering a therapeutic agent and/or an imaging agent to a vertebrate, and in particular, to a mammal, such as a human being.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: December 17, 2002
    Assignee: Gendel Limited
    Inventor: Anthony Patrick McHale
  • Patent number: 6485960
    Abstract: The present invention relates to the polycystic kidney disease 1 (PKD1) gene and its nucleic acid sequence, mutations thereof in patients having PKD1-associated disorders, the protein encoded by the PKD1 gene or its mutants, and their uses in disease diagnosis and therapy.
    Type: Grant
    Filed: April 14, 1995
    Date of Patent: November 26, 2002
    Assignee: Medical Research Council
    Inventors: Peter Charles Harris, Belen Peral, Christopher J. Ward, James Hughes, Martin Hendrik Breuning, Dorothea Johanna Maria Peters, Jeroen Hendrik Roelfsema, Julian Sampson, Dirkje Jorijntje Johanna Halley, Mark David Nellist, Lambertus Antonius Jacobus Janssen, Ajenne Lique Wilhelma Hesseling
  • Patent number: 6465199
    Abstract: This invention relates to methods and compositions for monitoring enzymatic activity as a function of the the interaction of binding partners, wherein binding is dependent upon addition or subtraction of a chemical moiety to or from one of the binding partners by a protein modifying enzyme.
    Type: Grant
    Filed: February 26, 1999
    Date of Patent: October 15, 2002
    Assignee: Cyclacel, Ltd.
    Inventors: Roger K. Craig, John Colyer
  • Patent number: 6392121
    Abstract: A gene amplification system based on plant viral genetic elements dramatically increases foreign protein production in plants. A safer and more economical production system for vaccines and antibodies in recombinant plants grown using agricultural practice is described. The high-level expression system uses the replicative process of a plant mastrevirus, exemplified by bean yellow dwarf virus (BeYDV). The expression system is preferably inducible to avoid interference with plant growth and development. Developmental cues, such as fruit ripening, are employed to trigger expression of the foreign protein using a tissue-specific promoter. A single, stably integrated expression cassette for foreign protein is replicated extrachromosomally in ripening fruit, forming hundreds of transcriptionally competent copies. Preferred plant hosts include tomato as a model system and soybean for production of large quantities of protein at high total protein levels.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: May 21, 2002
    Assignee: Boyce Thompson Institute for Plant Research
    Inventors: Hugh S. Mason, Kenneth E. Palmer, Kathleen L. Hefferon, Tsafrir S. Mor, Charles Arntzen
  • Patent number: 6387686
    Abstract: Methods are disclosed whereby protease activity is directly linked to delivery of a transferable label to a target cell which expresses a protease, via fusion of viral display packages comprising the transferable label with the target cell. The methods can be used, inter alia, to identify proteases, including previously undiscovered proteases or variants of known proteases which may have altered substrate specificity.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: May 14, 2002
    Assignee: BioFocus Discovery Limited
    Inventors: Mark P. Chadwick, Stephen J. Russell, Christian Buchholz
  • Patent number: 6380360
    Abstract: The present invention relates to the polycystic kidney disease 1 (PKD1) gene and its nucleic acid sequence, mutations thereof in patients having PKD1-associated disorders, the protein encoded by the PKD1 gene or its mutants, and their uses in disease diagnosis and therapy.
    Type: Grant
    Filed: March 31, 1998
    Date of Patent: April 30, 2002
    Assignee: Medical Research Council
    Inventors: Peter Charles Harris, Belen Peral, Christopher J. Ward, James Hughes, Martin Hendrik Breuning, Dorothea Johanna Maria Peters, Jeroen Hendrik Roelfsema, Julian Sampson, Dirkje Jorijntje Johanna Halley, Mark David Nellist, Lambertus Antonius Jacobus Janssen, Ajenne Lique Wilhelma Hesseling
  • Patent number: 6350580
    Abstract: The invention relates to a method of generating a signal indicative of the presence of a target nucleic acid sequence in a sample, where the method includes forming a cleavage structure by incubating a sample comprising a target nucleic acid sequence with a probe having a secondary structure that changes upon binding of the probe to the target nucleic acid sequence, and cleaving the cleavage structure with a nuclease to release a nucleic acid fragment to generate a signal, wherein generation of the signal is indicative of the presence of a target nucleic acid sequence in a sample.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: February 26, 2002
    Assignee: Stratagene
    Inventor: Joseph A. Sorge
  • Patent number: 6322976
    Abstract: The invention pertains to isolated nucleic acid molecules containing sequences specified herein, to mutant CD36 genes and their encoded gene products, to methods of screening blood or a blood product by detecting a CD36 gene mutation, methods of administering blood or a blood product based on the presence or absence of a CD36 gene mutation, to methods of matching a biological sample donor with a recipient based on detection of a mutation in the CD36 gene, methods of determining the resistance of a patient to infection by a parasite by detecting a CD36 gene mutation, methods of diagnosing a disease associated with a defect in insulin action, glucose metabolism, fatty acid metabolism, and/or catecholamine action by detecting a mutation in the CD36 gene, and methods of disease treatment by altering the mutation(s).
    Type: Grant
    Filed: March 17, 1999
    Date of Patent: November 27, 2001
    Assignees: Medical Research Council, SCIOS, Inc.
    Inventors: Timothy J. Aitman, James Scott, Lawrence W. Stanton
  • Patent number: 6297004
    Abstract: We have made retrovirus particles displaying a functional antibody fragment. We fused the gene encoding an antibody fragment directed against a hapten with that encoding the viral envelope protein (Pr80env) of the ecotropic Moloney murine leukemia virus. The fusion gene was co-expressed in ecotropic retroviral packaging cells with a retroviral plasmid carrying the neomycin phosphotransferase gene (neo), and retroviral particles with specific hapten biding activities were recovered. Furthermore the hapten-binding particles were able to transfer the neo gene and the antibody-envelope fusion gene to mouse fibroblasts. In principle, the display of antibody fragments on the surface of recombinant retroviral particles could be used to target virus to cells for gene delivery, or to retain the virus in target tissues, or for the construction of libraries of viral display packages.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: October 2, 2001
    Assignee: Cambridge Drug Discovery Holding, LTD
    Inventors: Stephen J. Russell, Robert E. Hawkins, Gregory P. Winter
  • Patent number: 6274310
    Abstract: Methods for screening a patient for pancreatic disease are disclosed and are based upon detection of a mutation in the gene encoding insulin promoter factor-1 (IPF-1) which is linked to diabetes mellitus and pancreatic agenesis.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: August 14, 2001
    Assignee: The General Hospital Corporation
    Inventors: Joel F. Habener, Doris A. Stoffers
  • Patent number: 6270761
    Abstract: Disclosed are various compositions for use in the delivery of nucleic acid to a target cell including: a composition comprising a calcium salt in particulate form, the nucleic acid to be delivered, and one or more further components to enhance the efficiency of delivery of the nucleic acid to a target cell, the nucleic acid and the one or more further components being complexed with the particulate calcium salt; and methods of delivering a nucleic acid to a target cell.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: August 7, 2001
    Assignee: Cambridge Drug Discovery Holdings, LTD
    Inventors: Stephen James Russell, Frances Joanne Morling
  • Patent number: 6264948
    Abstract: A method of suppressing tumor cell growth, comprising administering to a mammal in need thereof an amount of an inhibitor of eosinophilia sufficient to result in suppression of tumor cell growth is disclosed.
    Type: Grant
    Filed: December 8, 1998
    Date of Patent: July 24, 2001
    Assignee: Beth Israel Deaconess Hospital, Inc.
    Inventors: David T. W. Wong, Peter F. Weller
  • Patent number: 6224870
    Abstract: The invention provides compositions and methods for modulating immune responses in subjects. The invention is based, at least in part, on the discovery that an in-frame translation fusion of an antigen with an APC binding domain of an opsonin forms a molecule, that is, a fusion polypeptide, which when administered to a subject modulates an immune response to the antigen.
    Type: Grant
    Filed: January 15, 1998
    Date of Patent: May 1, 2001
    Assignee: Genitrix, Ltd.
    Inventor: Andrew H. Segal
  • Patent number: 6217846
    Abstract: Radioactively labeled peptides comprising oligopeptides of from 3 to 10 peptide units and containing the sequence RGD and particularly the oligopeptides RGDSY and RGDFY, are disclosed as in vivo thrombus, tumor or CAM markers for the in vivo diagnosis and detection of thrombi, tumors or CAM in mammals.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: April 17, 2001
    Assignee: Antisoma Research Limited
    Inventor: Alan William John Stuttle
  • Patent number: 6207374
    Abstract: Tuberous sclerosis (TSC) is an autosomal dominant disorder characterised by widespread development of growths in many tissues and organs. A gene (TSC2) is identified on chromosome 16 which is mutated in TSC and which may behave as a tumour suppressor. Screening of actual or suspected TSC patients for normal or mutated TSC2 can be used for diagnostic purposes. TSC2 protein (tuberin) may be used to treat or prevent unrestrained cell division and/or tumour development in patients with or without TSC.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: March 27, 2001
    Assignee: Medical Research Council
    Inventors: Julian R. Sampson, Mark David Nellist, Phillip Brook-Carter, Magitha Maheshwar, Dirkje Jorijnte Johanna Halley, Lambertus Antonius Jacobus Janssen, Arjenne Lique Wilhelma Hesseling, Anna Maria Wilhelmina van den Ouweland, Peter Charles Harris, Christopher James Ward, Martin Hendrik Breuning, Jeroen Hendrik Roelfsema
  • Patent number: 6149572
    Abstract: A centrifuge bowl for separating heavier particles from lighter particles and water comprises a first conical bowl wall leading to a pair of annular recesses at actually spaced positions. Each recess is generally re-shaped with an upper side wall, a lower side wall and a base. The base contains a plurality of angularly spaced discharge ducts each having a mouth projecting through the base into the interior of the bowl for collecting the heavier particles. A pinch valve is formed as an integral assembly with the mouth and duct and is mounted within a housing carried within the wall of the bowl. The housing, valve and duct can therefore be removed as a separate assembly by pulling from a chamber within the wall of the bowl. A compression fluid supply duct passes through the wall to communicate with the chamber.
    Type: Grant
    Filed: July 22, 1998
    Date of Patent: November 21, 2000
    Inventor: Benjamin Knelson
  • Patent number: 6114109
    Abstract: A synthetic molecule comprises at least one oligonucleotide, comprising and RNA binding sequence or sequences corresponding to the site bound by the HIV protein tat and capable of binding to tat within cells. The binding sequence or sequences, by binding tat within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients affected with HIV. The invention also provides an assay for identifying compounds that inhibit tat binding.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: September 5, 2000
    Assignee: RiboTargets, Ltd.
    Inventors: Jonathan Karn, Michael J. Gait, Shaun Heaphy, Colin Dingwall
  • Patent number: 6085767
    Abstract: A tent structure convertible from a hanging tent to a ground-based tent is herein described. The tent structure includes a top portion having slots, T-shaped connectors stitched into the base portion and resilient rods having ends arranged to be inserted into either the slots or the T-shaped members. For use as a hanging tent, the ends of the resilient rods are inserted into connectors on opposite sides of the tent such that the resilient rods extend across the base portion of the tent and the tent is then hung from support structure(s). As a result of this arrangement, the base of the tent is firmly supported by the resilient rods and the tent is supported above the ground. For use as a ground-based tent, the connectors are pivoted such that the connectors are adjacent to the sides of the tent and the resilient rods are inserted one end into a connector and a second end into a slot such that the resilient rods extend along the sides of the tent and support the top portion of the tent above the ground.
    Type: Grant
    Filed: July 7, 1998
    Date of Patent: July 11, 2000
    Inventor: Brent Maslow